Overview
PRME market data
Price History
PRME price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for PRME. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Prime Medicine Says FDA Clears IND Application For PM577a, Investigational In Vivo Prime Editor For Wilson Disease; Initial Clinical Data Expected In 2027Benzinga · Jul 23, 2026, 8:15 PM
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics CaseBenzinga · Jul 8, 2026, 5:35 PM
Penguin Solutions, Beazer Homes, Alibaba And Other Big Stocks Moving Higher On WednesdayBenzinga · Jul 8, 2026, 2:20 PM
Tribunal Declares Prime Medicine's PM657 Is Within It's "Field" As Defined By Agreement With Beam Therapeutics; Company Owes No Monetary Damages To BeamBenzinga · Jul 8, 2026, 12:10 PM
8-K filing — Prime Medicine, Inc. (PRME)SEC EDGAR · Jul 8, 2026, 12:02 PM
Iridium Communications, FuelCell Energy, Rocket Lab And Other Big Stocks Moving Higher On MondayBenzinga · Jun 29, 2026, 2:00 PM
This Caseys Analyst Turns Bullish; Here Are Top 3 Upgrades For MondayBenzinga · Jun 29, 2026, 12:45 PM
Prime Medicine Says FDA Grants Regenerative Medicine Advanced Therapy Designation To PM359, Investigational Autologous Prime Edited Hematopoietic Stem Cell Therapy For Treatment Of p47phox-deficient CGDBenzinga · Jun 22, 2026, 12:15 PM
Prime Medicine Receives New Zealand's Regulator Clearance For Its Clinical Trial Application For PM577a To Treat Wilson DiseaseBenzinga · Jun 18, 2026, 12:15 PM
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · Jun 15, 2026, 9:15 PM